BPROAD
(2025)Objective
Intensive systolic BP control (<120 mm Hg) vs standard control (<140 mm Hg) to reduce major cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.
Study Summary
• Targeting SBP <120 mm Hg in diabetic patients with cardiovascular risk significantly reduced the incidence of major cardiovascular events and stroke compared to targeting <140 mm Hg with similar adverse events, but symptomatic hypotension and hyperkalemia were more frequent in the intensive group.
Intervention
Intensive systolic BP target <120 mm Hg vs. standard target <140 mm Hg in patients with type 2 diabetes using individualized antihypertensive therapy.
Inclusion Criteria
Age ≥50 with type 2 diabetes, elevated SBP (≥130 mm Hg if on antihypertensives or ≥140 mm Hg if not), and increased cardiovascular risk (prior CVD, subclinical disease, ≥2 risk factors, or CKD with eGFR 30–60).
Study Design
Arms: Intensive BP Control vs. Standard BP Control
Patients per Arm: Intensive: 6414, Standard: 6407
Outcome
• Primary outcome (nonfatal stroke, MI, HF hospitalization/treatment, CV death): 1.65 vs. 2.09 events per 100 person-years (HR 0.79, 95% CI 0.69–0.90, P<0.001).• Stroke: HR 0.79.• MI: HR 0.84.• HF hospitalization/treatment: HR 0.66.• CV death: HR 0.76.• All-cause death: HR 0.95.• Albuminuria incidence: HR 0.87.• CKD progression: similar between groups.• Serious adverse events: ~36% both groups.• Symptomatic hypotension: 0.1% vs. <0.1% (P=0.05).• Hyperkalemia: 2.8% vs. 2.0% (P=0.003).
Bottom Line
Intensive systolic blood pressure control significantly reduced major cardiovascular events in patients with type 2 diabetes, without increasing serious adverse events.
Major Points
- BPROAD is the largest RCT specifically testing intensive BP control (<120 mmHg) in type 2 diabetes — 12,821 patients, median 4.2 years follow-up. Published NEJM 2025.
- Primary outcome (composite of nonfatal stroke, nonfatal MI, HF hospitalization, or CV death): HR 0.79 (95% CI 0.69-0.90, p<0.001) — a 21% relative risk reduction with intensive control.
- Stroke specifically was reduced (HR 0.79 for fatal/nonfatal stroke) — making BPROAD directly relevant to stroke prevention in diabetic patients.
- Critically, BPROAD confirms and extends SPRINT findings to diabetic patients — SPRINT explicitly EXCLUDED diabetes, leaving a major evidence gap that BPROAD fills.
- Achieved BP separation: mean SBP 121.6 mmHg (intensive) vs 133.2 mmHg (standard) — a ~12 mmHg difference, similar to SPRINT's ~13 mmHg separation.
- Only 60% of intensive-group patients achieved target SBP <120 mmHg — yet still showed significant benefit, suggesting even partial achievement of intensive targets is meaningful.
- No increase in serious adverse events overall (36.3% vs 36.5%) — allaying concerns about harm from intensive BP lowering in diabetes. Only hyperkalemia (2.8% vs 2.0%, p=0.003) and hypotension (0.1% vs <0.1%) were increased.
- No mortality benefit (all-cause mortality HR 0.95, not significant) — similar to SPRINT, where CV mortality was reduced but all-cause mortality was borderline.
- Conducted entirely in China — raises questions about generalizability to non-Asian populations with different dietary patterns, body composition, and CV risk profiles.
- Resolves the ACCORD BP controversy — ACCORD (2010) found no benefit of intensive BP control in diabetes but was underpowered (4,733 patients, factorial design with glycemic intervention). BPROAD with 2.7× the sample size definitively shows benefit.
Study Design
- Study Type
- Randomized, open-label, blinded-endpoint trial
- Randomization
- Yes
- Blinding
- Open-label with blinded adjudication of outcomes
- Sample Size
- 12821
- Follow-up
- Median 4.2 years
- Centers
- 145
- Countries
- China
Primary Outcome
Definition: Composite of nonfatal stroke, nonfatal myocardial infarction, hospitalization for heart failure, or death from cardiovascular causes
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 2.09 events per 100 person-years | 1.65 events per 100 person-years | 0.79 (0.69 to 0.90) | <0.001 |
Limitations & Criticisms
- Open-label design (PROBE) — knowledge of BP target could influence medication adjustments, lifestyle counseling, and other cardiovascular interventions differentially between arms.
- Only 60% of intensive-group patients achieved SBP <120 mmHg — significant non-compliance dilutes the true effect size. The ITT analysis reflects the 'offer' of intensive treatment, not the actual achievement.
- Conducted entirely in China — Chinese populations have different stroke subtypes (more intracranial atherosclerosis, hemorrhagic stroke), dietary salt intake, body composition, and medication responses. Generalizability to Western populations uncertain.
- No mortality benefit — the absence of all-cause mortality reduction (HR 0.95) despite a 21% CV event reduction raises questions about whether some deaths were reclassified or shifted to non-CV causes.
- COVID-19 pandemic overlap (enrollment 2019-2021) — remote visits during lockdowns may have affected BP measurement accuracy, medication adherence monitoring, and outcome ascertainment.
- Modest DBP difference between groups may confound interpretation — it's unclear whether the benefit is from SBP reduction specifically or overall BP lowering.
- No individual component of the composite reached significance independently — the benefit was driven by the composite. Individual endpoints (stroke, MI, HF, CV death) showed directionally favorable but non-significant HRs.
- Choice of antihypertensive agents was not standardized — left to treating physicians, introducing variability in drug classes (some agents like ACE inhibitors may have diabetes-specific benefits beyond BP lowering).
- Kidney outcomes were not significantly different — more intensive BP lowering may theoretically slow diabetic nephropathy, but BPROAD did not demonstrate this.
Citation
Bi Y, Li M, Liu Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med 2025;392:1155–1167.